购物车
您的购物车当前为空
Gentulizumab (Gensci-059) 是人源化IgG4抗体,特异性结合CD47。在人和猴子体内,Gentulizumab 展示出与CD47的高亲和力,有效抑制CD47-SIRPα相互作用,并表现出显著的抗肿瘤活性。Gentulizumab 的同型对照可参考 HumanIgG4(S228P) kappa, Isotype Control。
别名 金妥利珠单抗, Gentulizumab, Gensci-059
Gentulizumab (Gensci-059) 是人源化IgG4抗体,特异性结合CD47。在人和猴子体内,Gentulizumab 展示出与CD47的高亲和力,有效抑制CD47-SIRPα相互作用,并表现出显著的抗肿瘤活性。Gentulizumab 的同型对照可参考 HumanIgG4(S228P) kappa, Isotype Control。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | 待询 | 4-6周 | |
| 5 mg | 待询 | 4-6周 |
TargetMol的所有产品仅用作科学研究或药证申报,不能被用于人体,我们不向个人提供产品和服务。请您遵守承诺用途,不得违反法律法规规定用于任何其他用途。
| 产品描述 | Gentulizumab (Gensci-059) is a humanized IgG4 antibody that targets and binds to CD47. It demonstrates strong binding affinity to CD47 in both humans and monkeys and effectively inhibits the interaction between CD47 and SIRPα. Gentulizumab exhibits potent antitumor activity. For isotype control, refer to HumanIgG4(S228P) kappa, Isotype Control. |
| 别名 | 金妥利珠单抗, Gentulizumab, Gensci-059 |
| 反应种属 | Human |
| 应用 | ELISAFACSFunctional assay |
| 抗体种类 | Monoclonal |
| 缓冲液 | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| 内毒素 | <1.0 EU/mg |
| 偶联 | Unconjugated |
| 存储 | -20°C for 1 year Shipping with blue ice/Shipping at ambient temperature. 实际储存温度请以COA为准 |
对于不同动物的给药剂量换算,您也可以参考 更多